Durham, NC 的 多發性骨髓瘤 臨床試驗
37 項針對 多發性骨髓瘤 的研究正在 Durham（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Chapel Hill · 距離 10 英里
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 距離 10 英里
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
招募中2 期
- Duke University Medical Center, Durham
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Durham VAMC, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
招募中2/3 期
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 距離 10 英里
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- University of North Carolina Medical Center, Chapel Hill · 距離 10 英里
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
招募中1/2 期
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 距離 10 英里
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
招募中2 期
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 距離 13 英里
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
招募中1/2 期
- GSK Investigational Site, Chapel Hill · 距離 10 英里
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
招募中1 期
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Durham
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
招募中
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 距離 10 英里
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Durham
- Research Site, Chapel Hill · 距離 10 英里
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
招募中1 期
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 距離 10 英里
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
招募中1/2 期
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 距離 10 英里
Selinexor and Backbone Treatments of Multiple Myeloma Patients
招募中1/2 期
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- University of North Carolina /ID# 251203, Chapel Hill · 距離 10 英里
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
招募中2 期
- University of North Carolina (Data Collection Only), Chapel Hill · 距離 10 英里
Registry of Older Patients With Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
招募中2 期
- University of North Carolina, Chapel Hill · 距離 10 英里
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
招募中2 期
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 距離 10 英里
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
招募中1/2 期
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 距離 13 英里
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of North Carolina, Chapel Hill · 距離 10 英里
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
招募中1 期
- University of North Carolina, Chapel Hill · 距離 10 英里
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Duke University, Durham
- UNC Hospital, Chapel Hill · 距離 10 英里
Registry for Adults With Plasma Cell Disorders (PCD's)
招募中觀察性研究
- North Carolina Cancer Hospital, Chapel Hill · 距離 10 英里
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- Duke University Health System (DUHS), Durham
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA42 項研究
- Houston, TX38 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- Rochester, MN24 項研究
- St. Louis, MO24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Edison, NJ22 項研究
- Chicago, IL22 項研究
Durham 的其他研究
- 乳癌64 項研究
- 癌症（所有類型）58 項研究
- 非小細胞肺癌39 項研究
- 急性髓系白血病33 項研究
- 轉移性癌症33 項研究
- 前列腺癌32 項研究
- 肺癌32 項研究
- 大腸直腸癌28 項研究
- 卵巢癌27 項研究
- 慢性淋巴性白血病27 項研究
- 心臟衰竭26 項研究
- 胰臟癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。